Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?

Bristol Myers Squibb won FDA label expansion for Breyanzi to treat relapsed/refractory marginal zone lymphoma, making it the only CAR T therapy approved for five cancer types; Breyanzi sales doubled year-over-year, reaching $966 million in the first nine months of 2025 (up 100%). The approval and rapid commercial growth bolster BMY’s plan to offset revenue erosion from legacy drugs facing generics, but competitive pressure from Gilead’s Yescarta and Novartis’ Kymriah, a YTD share decline of 8.2%, and a below-industry forward P/E (8.63x vs. 16.95x) temper the near-term upside; Zacks’ consensus EPS revisions are mixed and BMY carries a Zacks Rank #3 (Hold).

Analysis

Market structure: Breyanzi’s fifth FDA indication materially strengthens BMY’s CAR‑T franchise and directly benefits BMY (BMY), contract CDMO/viral‑vector suppliers and high‑volume transplant centers; it pressures Novartis (NVS) and Gilead (GILD) in overlapping CD19 niches. Breyanzi’s $966M 9‑month run rate and label breadth improve BMY’s negotiating leverage with payors but pricing power is capped — expect net price pressure and prior‑authorization frictions to limit full list‑price capture over 12–24 months.

Risk assessment: Key tail risks are a) reimbursement cuts or CMS policy changes reducing per‑patient revenue, b) manufacturing disruptions (vector shortage or batch failures) that can cut realized volume by >20%, and c) competitor clinical readouts (YTB323 or Tecartus) showing superior durability. Immediate (days) volatility will track earnings/label headlines; short term (weeks–months) depends on uptake metrics and Q4 sales; long term (12–36 months) is driven by durable response data and scale economics.

Trade implications: Primary trade is a modest constructive BMY exposure given depressed multiples (forward P/E ~8.6x vs industry ~17x): use a 2–3% long equity or LEAP call (9–12 month). Relative‑value: long BMY vs short NVS (1:1 dollar) as NVS’s Kymriah sales are declining (-12% YTD) and faces pipeline execution risk. Use options to shape risk: buy BMY 12‑month LEAP calls combined with a 25–35% OTM short call to finance premium if neutral‑bullish.

Contrarian angles: Consensus underweights BMY’s ability to replace Revlimid revenue via label expansions; a successful EU/US rollout could re‑rate BMY toward mid‑teens P/E (implying >30% upside). Conversely, uptake may be lumpy — hospital capacity and payor uptake can delay revenue recognition, making near‑term sentiment reaction overdone. Historical CAR‑T rollouts show adoption curves that accelerate after year‑two reimbursement clarity; monitor hospital site activations and CMS coding updates as leading indicators.

Key Decisions for Investors

• Establish a 2–3% long position in Bristol Myers Squibb (BMY) using either stock or buy 1‑year LEAP calls (strike ~10–15% OTM) within the next 2–6 weeks; target a 30–45% upside over 12–18 months if EPS guidance stabilizes and Breyanzi maintains >30% YoY growth; set stop‑loss at 20% below entry or if management cuts FY guidance.
• Implement a pair trade: go long BMY (equal dollar) and short Novartis (NVS) for a 6–12 month horizon to capture relative execution on CAR‑T; size net exposure to 1–2% of portfolio and tighten stops if BMY/NVS spread moves <‑10% or new positive Kymriah data emerges for NVS.
• Use options to express a downside on competitors: buy a 6–9 month Gilead (GILD) put spread (sell nearer‑term put, buy further OTM) sized to 0.5–1% portfolio risk; profit if GILD cannibalized in CD19 or posts disappointing growth.
• Monitor three 30–90 day catalysts before increasing size: monthly hospital site activation counts (target: accelerating MoM adds), CMS reimbursement updates (any negative policy = cut exposure), and next quarterly Breyanzi net product revenue (failure to grow >20% QoQ = re‑evaluate).